Friday, August 27, 2021 1:12:24 PM
Phase 3, close to EUA or close to market (13 programs)
1. Abivertinib NSCLC NDA filed China
2. Abivertinib NSCLC ph.3 completed US
3. PD-L1 SCLC partnered
4. Erbitux biosimilar
5. Xolair biosimilar
6. Remicade biosimilar(approved in China. SRNE holds ROW rights!)
7. SP-102 sciatica
8. RTX Osteo Arthritis
9. RTX cancer pain
10. Covi-Stix EUA application(approval in Mexico...25million shipped!)DOD CRADA
11. Covi-Trace EUA application
12. Sofusa Enbrel
13. Cynviloq (part of PSS lawsuit)
Phase 2 (13 programs)
1. Seprehvir Oncolytic virus
2. Covi-MSC EUA potential
3. Covi-AMG EUA potential DOD CRADA
4. COVIDROPS EUA potential DOD CRADA
5. Covi-Track EUA pre-validation DOD CRADA
6. PD-L1 partnered
7. Herceptin delivery partnered
8. Abivertinib Lymphoma
9. Abivertinib Covid 19 EUA potential as soon as August
10. Abivertinib prostate cancer ph.2 IND
11. Abivertinib Lupus ph.2 IND
12. Abivertinib hairy cell leukemia
13. CD47 partnered
Phase 1, IND filed or pre-IND (38+ programs)
1. Seprehvec Oncolytic Virus
2. CD 38 CAR-T ph.1
3. CEA CAR-T ph.1
4. CD38 DAR-T ph.1
5. BCMA DAR-T pre-IND
6. PD-L1(C/DAR-T) pre-IND
7. CyCART-19 partnered
8. Covi-GeneMab pre-IND $34 million DARPA funding
9. PD1-GeneMab pre-IND
10. ERT (Enzyme Replacement Therapy) several pre IND programs
11. IL2Teff pre-IND
12. IL2Treg pre-IND
13. Sofusa anti-PD1 and anti-CTLA4
14. TNF-a (Enbrel) ph.1
15. CTLA-4 (Yervoy)
16. CD47 ph.1 basket trial partnered
17. TROP2 IND granted in China...partnered.
18. BCMA ADC pre-IND
19. ROR1 ADC pre-IND
20. CD25 ADNAB pre-IND
21. CD20 ADNAB (Rituxan) IIT-ph.1
22. VEGF(Avastin) ADNAB IIT-ph.1
23. PD-L1 ADNAB pre-IND
24. VEGFR2 ADNAB pre-IND
25. CBD immune diseases pre-IND
26. CBD insomnia pre-IND
27. CBD Parkinsons pre-IND
28. CBD CNS diseases pre-IND
29. PD-L1 CAR-NK partnered
30. CD38 CAR-NK to be partnered
31. CD38 ADC AL Amyloidosis
32. AC0058 ph.1b lupus
33. AC0058 pre-IND MS
34. AC0939 pre-IND CNS indications
35. A166 HER2 ADC phase 1
36. Karolinska off-the-shelf DAR-NK pre-IND
37. Covid mRNA vaccine(Sofusa delivery)
37. 1,000,000+ small molecule library
38. Twenty quadrillion antibody library
FUNDING? Sorrento has invested wisely and has 8.2 million shares of ImmunityBio, 20.4 million shares of Celularity and 35% of ImmuneOncia. These are worth many hundreds of millions and the PSS binding arbitration will be settled with very large potential gains. And it has many attractive programs to partner for upfront, milestone and royalty payments! The first of many EUA's will produce revenues within weeks(Mexico)as 25 million testkits are being shipped. Huge portfolio AND huge assets! Sorrento is in the early days of becoming(or being acquired by...) a Big Pharma!
"The refusal of the real is the number one dogma of our time" Rene Girard
Recent SRNE News
- Form 8-K - Current report • Edgar (US Regulatory) • 11/03/2023 09:31:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/27/2023 08:15:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/13/2023 01:51:06 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/28/2023 09:25:07 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/07/2023 08:15:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/01/2023 10:01:54 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/13/2023 10:26:26 AM
- Shanghai Escugen Biotechnology Co., Ltd., a partner of Levena Biopharma, a Sorrento Company, releases positive results from a first-in-human study of ESG401, a TROP2 Antibody Drug Conjugate in patients with locally advanced/metastatic solid tumors at the A • GlobeNewswire Inc. • 06/05/2023 01:00:00 PM
Green Leaf Innovations, Inc. Engages Olayinka Oyebola & Co for Two-Year Audit • GRLF • May 28, 2024 8:30 AM
HealthLynked Introduces AI-Powered Chat Function to Enhance Healthcare Accessibility • HLYK • May 28, 2024 8:00 AM
Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM